Systemic Lupus Erythematosus (SLE)

Participant Criteria:

  • Study evaluating the safety and effects of two injectable doses of LY2127399 versus placebo in patients with SLE.
  • Adults 18 years or older.
  • Sixteen study visits during the 12 month trial duration with the option of continuing in an open label extension after completion of the study.

If you meet the criteria for this trial and would like more information you can fill out the form below and click on the "Submit" button or call Gina Kavanaugh at (757) 969-5885.